marginal zone lymphoma
July 13, 2022
ASCO 2022 Lymphoma In-Depth BookmarkGeorge Lundberg, MD
Presented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.
July 1, 2022
Early Study Finds New Lymphoma Drug Effective BookmarkGeorge Lundberg, MD
According to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.